FDA Black-Box Warning for ADHD Stimulants: What's True Now

No, the FDA has not finalized a new cardiac-specific black-box warning for ADHD stimulants as of this writing. The most recent confirmed, class-wide boxed-warning change took effect in 2023 and addresses misuse, abuse, addiction, and overdose, not a new cardiac-risk designation. A claim circulating online about a “May 2026” FDA advisory committee vote recommending a cardiac black-box warning describes numbers — an 8-7 vote, a 15-0 vote for a medication guide, 25 reported sudden deaths — that match a documented FDA advisory committee vote from February 2006, not a new 2026 event. This post separates what the label currently says from what that older, recirculated vote actually was, and gives you a way to check for real updates going forward.

Photo by National Cancer Institute on Unsplash

What the current stimulant label actually says

Prescription stimulant labeling has two separate cardiovascular-related elements worth distinguishing:

• A long-standing Warnings and Precautions caution. Current labels for stimulants such as Adderall XR advise against use in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems, and note that sudden death has been reported in such patients taking stimulants at recommended doses [1]. This has been part of stimulant labeling for years; it is not a new 2026 addition.
• The 2023 class-wide boxed warning update. In May 2023, FDA required that all prescription stimulant labels carry a consistent boxed warning addressing the risk of misuse, abuse, addiction, and overdose, along with more consistent instructions for clinicians to assess and reassess each patient’s risk before and during treatment [2]. This is the most recent confirmed class-wide boxed-warning change.
• A narrower 2025 update. In 2025, FDA also required expanded labeling on the risk of weight loss and other adverse reactions in children younger than 6 taking extended-release stimulants, a population for which these products are not approved but are sometimes prescribed off-label [3].

Neither of these confirmed updates added a new cardiac-specific black-box designation. If your documentation habits already address cardiac history, the current label changes don’t require a different workflow — they reinforce the misuse-risk assessment and reassessment already covered in our ADHD documentation for stimulant prescribing guide.

Where the “2026 advisory committee vote” claim comes from

Several 2026-dated articles describe an FDA Drug Safety and Risk Management Advisory Committee vote of 8-7 to recommend a black-box cardiac warning on stimulants, plus a 15-0 vote to add a medication guide, following FDA medical officers’ review of 25 reported sudden deaths [4][5]. Those exact figures — 8-7, 15-0, 25 sudden deaths — match a well-documented FDA advisory committee meeting that took place on February 9, 2006, not 2026 [6][7]. That 2006 vote is extensively covered in contemporaneous reporting: Psychiatric Times reported the panel narrowly voting for a black-box warning, and a subsequent Pediatric Advisory Committee meeting in March 2006 ultimately did not adopt the black-box recommendation, instead favoring added label language and a patient medication guide [8][9].

We could not find a primary FDA source — a Drug Safety Communication, a Federal Register notice, or an FDA advisory committee meeting record for 2026 — confirming a new cardiac-focused vote this year [10]. The Drug Safety and Risk Management Advisory Committee itself was administratively renewed for another two-year charter term in May 2026, which is a routine procedural action, not a meeting outcome [11]. Our working conclusion, checked against multiple sources, is that some 2026-dated web content is republishing or restating the 2006 vote without updating the year, and that has fed the “2026 advisory vote” framing now circulating. If you’ve seen this claim from a patient, a colleague, or an AI-generated summary, it’s worth tracing back to a primary FDA source before treating it as current.

Try it with your next patient. AxonCPT gives you 2 free tests every month — no card required. Send a link, your patient finishes in ~16 minutes from home, and you get a norm-referenced report instantly. Create your free account →

Why this matters for your documentation regardless

Whether or not a new cardiac black-box warning is ever finalized, the underlying clinical practice it would formalize is already good practice and, for the misuse-related boxed warning, already required by the current label:

• Take a cardiac history and family history of sudden death or serious arrhythmia before starting a stimulant, and document it [1].
• Assess and document misuse, abuse, and addiction risk before prescribing, and reassess it over the course of treatment, per the 2023 update [2].
• Record vital signs at appropriate intervals, since stimulants have dose-dependent effects on heart rate and blood pressure that current labels already flag.
• Note in the chart that you discussed these risks with the patient as part of informed consent.

None of this depends on the 2026 claim being true. If a genuine new cardiac warning is finalized later, the practical documentation response — cardiac history, family history, vital-sign monitoring, informed discussion — is the same set of elements a defensible chart should already contain.

How to verify this yourself going forward

Because FDA labeling and advisory committee activity does change over time, don’t take any single blog post — including this one — as the final word. Check directly:

1. FDA Drug Safety Communications archive, which lists dated safety communications by year [10].
2. The FDA Advisory Committee Calendar, which posts upcoming and past meeting materials, including voting questions and outcomes, for the Drug Safety and Risk Management Advisory Committee [11].
3. The Federal Register, which publishes advisory committee meeting notices and any final rule or labeling change.
4. Drugs@FDA, for the current approved label of the specific stimulant product you prescribe, since label language can be updated at the product level even without a new class-wide safety communication.

If FDA does finalize a new cardiac-specific boxed warning, update your intake and consent materials and re-screen existing patients per the new label language, the same way practices did after the 2023 misuse-related update.

How this looks in practice

A psychiatrist or PMHNP who hears about this claim from a patient or a news summary can work through it the same way:

1. Don’t repeat the claim as fact in the chart or to the patient until you’ve traced it to a primary FDA source.
2. Confirm the current label for the specific product via Drugs@FDA, since that’s what actually governs prescribing information.
3. Keep doing the cardiac and misuse-risk documentation the current label already requires, regardless of what happens with any future warning.
4. Use objective, repeatable data to support the rest of the chart. A cardiac risk assessment is a separate clinical task from an attention/impulsivity measure, but both belong in a complete record. With objective ADHD testing with AxonCPT, a patient completes a standardized test from home in about 16 minutes, and the norm-referenced report gives you a dated data point to pair with your documented risk assessment and rating scales. You can see what the report looks like before deciding whether it fits your workflow.

Frequently asked questions

Has the FDA added a black-box cardiac warning to ADHD stimulants in 2026? Not based on any primary FDA source we could locate as of this writing. The specific vote details (8-7, 15-0, 25 sudden deaths) circulating under a “2026” label match a documented February 2006 advisory committee vote. Check FDA.gov directly for the current status before relying on this claim [6][7][10].

What is the most recent confirmed change to stimulant labeling? A May 2023 class-wide boxed-warning update addressing misuse, abuse, addiction, and overdose risk, plus a 2025 update expanding labeling on weight-loss risk for children under 6 on extended-release stimulants [2][3].

Do current stimulant labels already mention cardiac risk? Yes. Current labels already advise against stimulant use in patients with known serious structural cardiac abnormalities or other serious cardiac disease, and note reports of sudden death in such patients at recommended doses. This is existing Warnings and Precautions language, not a new 2026 boxed-warning addition [1].

Should I change how I screen patients for cardiac risk while this is unresolved? No. Continue taking a cardiac and family history before prescribing, as current labeling already recommends, and document it. That practice doesn’t depend on whether a new warning is finalized [1][2].

Can an objective test like a CPT detect cardiac risk? No. A continuous performance test measures attention, impulsivity, and response variability — it says nothing about cardiac status. Cardiac risk assessment is a separate clinical task (history, exam, and where indicated, cardiology referral) that a CPT does not replace. See what a continuous performance test is for what a CPT does and doesn’t measure.

Start testing your patients with AxonCPT

Regulatory headlines change, but the documentation fundamentals — a clear diagnostic basis, a documented risk assessment, and an objective way to track response — don’t. AxonCPT adds a standardized, norm-referenced attention measure to that record, with 2 free tests every month and no card required. Create your free AxonCPT account or learn more at axoncpt.com.

References

1. U.S. Food and Drug Administration. Adderall XR prescribing information. Revised October 2023. (Check Drugs@FDA for the current label of the product you prescribe.)
2. U.S. Food and Drug Administration. FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. Drug Safety Communication, May 11, 2023.
3. U.S. Food and Drug Administration. FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants. Drug Safety Communication, 2025.
4. Contemporary Pediatrics. Upcoming for ADHD meds: Black box warning?. Accessed September 2026.
5. Worst Pills, Best Pills (Public Citizen). FDA Issues Stronger Warnings for ADHD Stimulants; Warnings Don’t Go Far Enough.
6. Psychiatric Times. FDA Panel: No Black Box Warning for ADHD Drugs.
7. American Academy of Pediatrics, AAP News. FDA panel recommends black box warning on ADHD stimulant medications.
8. Psychiatric Times. ADHD Drugs: Label Cautions, but No Black Box.
9. NBC News. Strongest warnings on ADHD drugs rejected.
10. U.S. Food and Drug Administration. Drug Safety Communications archive. Accessed September 2026.
11. Federal Register. Advisory Committee; Drug Safety and Risk Management Advisory Committee; Renewal. May 26, 2026.